Company: RPID
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0001380106-25-000089
Chunk: 26

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 26
---
-administer injectable formats, as well as on the boards of the Commonwealth School and Well Sense Health Plan. Mr. Schwartz also previously served on the board of directors of SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) from August 2017 to August 2023. Mr. Schwartz holds an M.B.A. from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar, and holds a B.A. in economics from Yale University. We believe that Mr. Schwartz’s extensive industry and transactional experience qualify him to serve on our Board.

| RICHARD KOLLENDER |     | Age 55 |

Richard Kollender has served as a member of our Board since July 2009, except for the period from February 2017 to October 2018. From August 2016 to September 2018, Mr. Kollender served as our Chief Business Officer and Chief Financial Officer. Since April 2024, Mr. Kollender has served as the Chief Executive Officer and a director of Reaction Biology Corporation, where he also served as Chief Financial Officer and Chief Business Officer from April 2022 through December 2024. Mr. Kollender served on the board of directors of Strongbridge Biopharma plc, a biopharmaceutical company, from March 2015 to September 2019, where he also served as Chief Operating Officer from September 2019 to March 2021, and as President and Chief Financial Officer from March 2021 to March 2022. Strongbridge Biopharma plc was acquired by Xeris Pharmaceuticals Inc. in October of 2021 and Mr. Kollender agreed to remain with the company through March 2022. Since January 2011, he has served as a Partner and Executive Manager of Quaker Partners Management, LP, a healthcare investment firm, which he initially joined in 2003. Since 2019, Mr. Kollender has also served on the board of directors of Ocugenix Corporation, a privately-held, clinical-stage ophthalmology company. Mr. Kollender previously served as a director of Celator Pharmaceuticals, Inc., currently a subsidiary of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), Nupathe, Inc., and Insmed, Inc. (Nasdaq: INSM). Mr. Kollender holds a B.A. in accounting from Franklin and Marshall College and an M.B.A. and a certificate degree in the graduate